Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 65
Filter
1.
Osteoporos Int ; 33(11): 2397-2408, 2022 Nov.
Article in English | MEDLINE | ID: mdl-35904681

ABSTRACT

Children with sickle cell disease (SCD) have the potential for extensive and early-onset bone morbidity. This study reports on the diversity of bone morbidity seen in children with SCD followed at three tertiary centers. IV bisphosphonates were effective for bone pain analgesia and did not trigger sickle cell complications. INTRODUCTION: To evaluate bone morbidity and the response to intravenous (IV) bisphosphonate therapy in children with SCD. METHODS: We conducted a retrospective review of patient records from 2003 to 2019 at three Canadian pediatric tertiary care centers. Radiographs, magnetic resonance images, and computed tomography scans were reviewed for the presence of avascular necrosis (AVN), bone infarcts, and myositis. IV bisphosphonates were offered for bone pain management. Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA). RESULTS: Forty-six children (20 girls, 43%) had bone morbidity at a mean age of 11.8 years (SD 3.9) including AVN of the femoral (17/46, 37%) and humeral (8/46, 17%) heads, H-shaped vertebral body deformities due to endplate infarcts (35/46, 76%), and non-vertebral body skeletal infarcts (15/46, 32%). Five children (5/26, 19%) had myositis overlying areas of AVN or bone infarcts visualized on magnetic resonance imaging. Twenty-three children (8/23 girls) received IV bisphosphonate therapy. They all reported significant or complete resolution of bone pain. There were no reports of sickle cell hemolytic crises, pain crises, or stroke attributed to IV bisphosphonate therapy. CONCLUSION: Children with SCD have the potential for extensive and early-onset bone morbidity. In this series, IV bisphosphonates were effective for bone pain analgesia and did not trigger sickle cell complications.


Subject(s)
Anemia, Sickle Cell , Myositis , Osteonecrosis , Anemia, Sickle Cell/complications , Anemia, Sickle Cell/pathology , Canada , Child , Diphosphonates/adverse effects , Female , Humans , Infarction/complications , Pain/drug therapy , Pain/etiology
2.
Schizophr Res ; 208: 390-396, 2019 06.
Article in English | MEDLINE | ID: mdl-30777603

ABSTRACT

INTRODUCTION: A faster and more accurate self-report screener for early psychosis is needed to promote early identification and intervention. METHODS: Self-report Likert-scale survey items were administered to individuals being screened with the Structured Interview for Psychosis-risk Syndromes (SIPS) and followed at eight early psychosis clinics. An a priori analytic plan included Spectral Clustering Analysis to reduce the item pool, followed by development of Support Vector Machine (SVM) classifiers. RESULTS: The cross-validated positive predictive value (PPV) of the EPSI at the default cut-off (76.5%) exceeded that of the clinician-administered SIPS (68.5%) at separating individuals who would not convert to psychosis within 12 months from those who either would convert within 12 months or who had already experienced a first episode psychosis (FEP). When used in tandem with the SIPS on clinical high risk participants, the EPSI increased the combined PPV to 86.6%. The SVM classified as FEP/converters only 1% of individuals in non-clinical and 4% of clinical low risk populations. Sensitivity of the EPSI, however, was 51% at the default cut-off. DISCUSSION: The EPSI identifies, comparably to the SIPS but in less time and with fewer resources, individuals who are either at very high risk to develop a psychotic disorder within 12 months or who are already psychotic. At its default cut-off, EPSI misses 49% of current or future psychotic cases. The cut-off can, however, be adjusted based on purpose. The EPSI is the first validated assessment to predict 12-month psychotic conversion. An online screening system, www.eps.telesage.org, is under development.


Subject(s)
Diagnosis, Computer-Assisted , Internet , Machine Learning , Psychotic Disorders/diagnosis , Early Diagnosis , Humans , Predictive Value of Tests , Psychotic Disorders/psychology , Risk Assessment , Support Vector Machine
3.
Mol Psychiatry ; 23(8): 1764-1772, 2018 08.
Article in English | MEDLINE | ID: mdl-29311665

ABSTRACT

Scientists have long sought to characterize the pathophysiologic basis of schizophrenia and develop biomarkers that could identify the illness. Extensive postmortem and in vivo neuroimaging research has described the early involvement of the hippocampus in the pathophysiology of schizophrenia. In this context, we have developed a hypothesis that describes the evolution of schizophrenia-from the premorbid through the prodromal stages to syndromal psychosis-and posits dysregulation of glutamate neurotransmission beginning in the CA1 region of the hippocampus as inducing attenuated psychotic symptoms and initiating the transition to syndromal psychosis. As the illness progresses, this pathological process expands to other regions of the hippocampal circuit and projection fields in other anatomic areas including the frontal cortex, and induces an atrophic process in which hippocampal neuropil is reduced and interneurons are lost. This paper will describe the studies of our group and other investigators supporting this pathophysiological hypothesis, as well as its implications for early detection and therapeutic intervention.


Subject(s)
Hippocampus/physiopathology , Schizophrenia/physiopathology , Animals , Hippocampus/diagnostic imaging , Humans , Models, Neurological , Schizophrenia/diagnosis
4.
Schizophr Res ; 197: 516-521, 2018 07.
Article in English | MEDLINE | ID: mdl-29358019

ABSTRACT

Machine learning techniques were used to identify highly informative early psychosis self-report items and to validate an early psychosis screener (EPS) against the Structured Interview for Psychosis-risk Syndromes (SIPS). The Prodromal Questionnaire-Brief Version (PQ-B) and 148 additional items were administered to 229 individuals being screened with the SIPS at 7 North American Prodrome Longitudinal Study sites and at Columbia University. Fifty individuals were found to have SIPS scores of 0, 1, or 2, making them clinically low risk (CLR) controls; 144 were classified as clinically high risk (CHR) (SIPS 3-5) and 35 were found to have first episode psychosis (FEP) (SIPS 6). Spectral clustering analysis, performed on 124 of the items, yielded two cohesive item groups, the first mostly related to psychosis and mania, the second mostly related to depression, anxiety, and social and general work/school functioning. Items within each group were sorted according to their usefulness in distinguishing between CLR and CHR individuals using the Minimum Redundancy Maximum Relevance procedure. A receiver operating characteristic area under the curve (AUC) analysis indicated that maximal differentiation of CLR and CHR participants was achieved with a 26-item solution (AUC=0.899±0.001). The EPS-26 outperformed the PQ-B (AUC=0.834±0.001). For screening purposes, the self-report EPS-26 appeared to differentiate individuals who are either CLR or CHR approximately as well as the clinician-administered SIPS. The EPS-26 may prove useful as a self-report screener and may lead to a decrease in the duration of untreated psychosis. A validation of the EPS-26 against actual conversion is underway.


Subject(s)
Machine Learning , Prodromal Symptoms , Psychiatric Status Rating Scales/standards , Psychotic Disorders/diagnosis , Schizophrenia/diagnosis , Self Report/standards , Adolescent , Adult , Female , Humans , Interview, Psychological , Longitudinal Studies , Male , Risk , Young Adult
5.
Sci Rep ; 7(1): 11165, 2017 09 11.
Article in English | MEDLINE | ID: mdl-28894214

ABSTRACT

Diabetic nephropathy is still a common complication of type 2 diabetes mellitus (T2DM) and improvement of endothelial dysfunction (ED) and inhibition of reactive oxygen species (ROS) are considered important targets for new therapies. Recently, we developed a new class of compounds (Sul compounds) which inhibit mitochondrial ROS production. Here, we tested the therapeutic effects of Sul-121 on ED and kidney damage in experimental T2DM. Diabetic db/db and lean mice were implanted with osmotic pumps delivering Sul-121 (2.2 mg/kg/day) or vehicle from age 10 to 18 weeks. Albuminuria, blood pressure, endothelial mediated relaxation, renal histology, plasma creatinine, and H2O2 levels were assessed. Sul-121 prevented progression of albuminuria and attenuated kidney damage in db/db, as evidenced by lower glomerular fibronectin expression (~50%), decreased focal glomerular sclerosis score (~40%) and normalization of glomerular size and kidney weight. Further, Sul-121 restored endothelium mediated vasorelaxation through increased production of Nitric Oxide production and normalized plasma H2O2 levels. Sul-121 treatment in lean mice demonstrated no observable major side-effects, indicating that Sul-121 is well tolerated. Our data show that Sul-121 inhibits progression of diabetic kidney damage via a mechanism that involves restoration of endothelial function and attenuation of oxidative stress.


Subject(s)
Antioxidants/administration & dosage , Chromans/administration & dosage , Diabetes Mellitus, Experimental/complications , Diabetic Nephropathies/drug therapy , Diabetic Nephropathies/prevention & control , Endothelium/physiology , Kidney/pathology , Piperazines/administration & dosage , Albuminuria/prevention & control , Animals , Histocytochemistry , Hydrogen Peroxide/analysis , Kidney Function Tests , Mice , Treatment Outcome
6.
Psychol Med ; 47(11): 1923-1935, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28249639

ABSTRACT

BACKGROUND: DSM-5 proposes an Attenuated Psychosis Syndrome (APS) for further investigation, based upon the Attenuated Positive Symptom Syndrome (APSS) in the Structured Interview for Psychosis-Risk Syndromes (SIPS). SIPS Unusual Thought Content, Disorganized Communication and Total Disorganization scores predicted progression to psychosis in a 2015 NAPLS-2 Consortium report. We sought to independently replicate this in a large single-site high-risk cohort, and identify baseline demographic and clinical predictors beyond current APS/APSS criteria. METHOD: We prospectively studied 200 participants meeting criteria for both the SIPS APSS and DSM-5 APS. SIPS scores, demographics, family history of psychosis, DSM Axis-I diagnoses, schizotypy, and social and role functioning were assessed at baseline, with follow-up every 3 months for 2 years. RESULTS: The conversion rate was 30% (n = 60), or 37.7% excluding participants who were followed under 2 years. This rate was stable across time. Conversion time averaged 7.97 months for 60% who developed schizophrenia and 15.68 for other psychoses. Mean conversion age was 20.3 for males and 23.5 for females. Attenuated odd ideas and thought disorder appear to be the positive symptoms which best predict psychosis in a logistic regression. Total negative symptom score, Asian/Pacific Islander and Black/African-American race were also predictive. As no Axis-I diagnosis or schizotypy predicted conversion, the APS is supported as a distinct syndrome. In addition, cannabis use disorder did not increase risk of conversion to psychosis. CONCLUSIONS: NAPLS SIPS findings were replicated while controlling for clinical and demographic factors, strongly supporting the validity of the SIPS APSS and DSM-5 APS diagnosis.


Subject(s)
Disease Progression , Prodromal Symptoms , Psychotic Disorders/physiopathology , Schizophrenia/physiopathology , Adolescent , Adult , Female , Humans , Longitudinal Studies , Male , Prognosis , Psychotic Disorders/diagnosis , Risk , Schizophrenia/diagnosis , Young Adult
7.
Transplant Proc ; 49(1): 218-220, 2017.
Article in English | MEDLINE | ID: mdl-28104142

ABSTRACT

Extracorporeal membrane oxygenation (ECMO) may be used safely as a bridge to lung transplantation in carefully selected elderly patients. We report the case of a 70-year-old patient bridged on ECMO before transplantation. A brief discussion on improving outcomes for the elderly and patients bridged on ECMO in general is presented.


Subject(s)
Extracorporeal Membrane Oxygenation/methods , Lung Transplantation , Preoperative Care/methods , Aged , Humans , Male , Treatment Outcome
8.
Psychol Med ; 46(14): 2907-2918, 2016 10.
Article in English | MEDLINE | ID: mdl-27050714

ABSTRACT

BACKGROUND: Social functioning (SF) difficulties are ubiquitous among individuals at clinical high risk for psychosis (CHR), but it is not yet clear why. One possibility is suggested by the observation that effective SF requires adaptive emotion awareness and regulation. Previous reports have documented deficits in emotion awareness and regulation in individuals with schizophrenia, and have shown that such deficits predicted SF. However, it is unknown whether these deficits are present prior to the onset of psychosis or whether they are linked to SF in CHR individuals. METHOD: We conducted a cross-sectional comparison of emotion awareness and regulation in 54 individuals at CHR, 87 with schizophrenia and 50 healthy controls (HC). Then, within the CHR group, we examined links between emotion awareness, emotion regulation and SF as indexed by the Global Functioning Scale: Social (Cornblatt et al. 2007). RESULTS: Group comparisons indicated significant differences between HC and the two clinical groups in their ability to identify and describe feelings, as well as the use of suppression and reappraisal emotion-regulation strategies. Specifically, the CHR and schizophrenia groups displayed comparable deficits in all domains of emotion awareness and emotion regulation. A hierarchical multiple regression analysis indicated that difficulties describing feelings accounted for 23.2% of the SF variance. CONCLUSIONS: The results indicate that CHR individuals display substantial emotion awareness and emotion-regulation deficits, at severity comparable with those observed in individuals with schizophrenia. Such deficits, in particular difficulties describing feelings, predate the onset of psychosis and contribute significantly to poor SF in this population.


Subject(s)
Affective Symptoms/physiopathology , Interpersonal Relations , Psychotic Disorders/physiopathology , Schizophrenia/physiopathology , Self-Control , Adult , Affective Symptoms/etiology , Cross-Sectional Studies , Female , Humans , Male , Psychotic Disorders/complications , Schizophrenia/complications , Young Adult
9.
Mol Psychiatry ; 19(1): 20-9, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24166406

ABSTRACT

Currently, all treatments for schizophrenia (SCZ) function primarily by blocking D(2)-type dopamine receptors. Given the limitations of these medications, substantial efforts have been made to identify alternative neurochemical targets for treatment development in SCZ. One such target is brain glutamate. The objective of this article is to review and synthesize the proton magnetic resonance spectroscopy ((1)H MRS) and positron emission tomography (PET)/single-photon emission computed tomography (SPECT) investigations that have examined glutamatergic indices in SCZ, including those of modulatory compounds such as glutathione (GSH) and glycine, as well as data from ketamine challenge studies. The reviewed (1)H MRS and PET/SPECT studies support the theory of hypofunction of the N-methyl-D-aspartate receptor (NMDAR) in SCZ, as well as the convergence between the dopamine and glutamate models of SCZ. We also review several advances in MRS and PET technologies that have opened the door for new opportunities to investigate the glutamate system in SCZ and discuss some ways in which these imaging tools can be used to facilitate a greater understanding of the glutamate system in SCZ and the successful and efficient development of new glutamate-based treatments for SCZ.


Subject(s)
Drug Discovery , Glutamic Acid/metabolism , Schizophrenia/metabolism , Schizophrenia/pathology , Animals , Humans , Neuroimaging
10.
Mol Psychiatry ; 18(8): 909-15, 2013 Aug.
Article in English | MEDLINE | ID: mdl-22869037

ABSTRACT

Dopamine (DA) has a role in the pathophysiology of schizophrenia and addiction. Imaging studies have indicated that striatal DA release is increased in schizophrenia, predominantly in the precommissural caudate (preDCA), and blunted in addiction, mostly in the ventral striatum (VST). Therefore, we aimed to measure striatal DA release in patients with comorbid schizophrenia and substance dependence. We used [(11)C]raclopride positron emission tomography and an amphetamine challenge to measure baseline DA D2-receptor availability (BPND) and its percent change post-amphetamine (ΔBPND, to index amphetamine-induced DA release) in striatal subregions in 11 unmedicated, drug-free patients with both schizophrenia and substance dependence, and 15 healthy controls. There were no significant group differences in baseline BPND. Linear mixed modeling using ΔBPND as the dependent variable and striatal region of interest as a repeated measure indicated a significant main effect of diagnosis, F(1,24)=8.38, P=0.008, with significantly smaller ΔBPND in patients in all striatal subregions (all P ≤ 0.04) except VST. Among patients, change in positive symptoms after amphetamine was significantly associated with ΔBPND in the preDCA (rs=0.69, P=0.03) and VST (rs=0.64, P=0.05). In conclusion, patients with comorbid schizophrenia and substance dependence showed significant blunting of striatal DA release, in contrast to what has been found in schizophrenia without substance dependence. Despite this blunting, DA release was associated with the transient amphetamine-induced positive-symptom change, as observed in schizophrenia. This is the first description of a group of patients with schizophrenia who display low presynaptic DA release, yet show a psychotic reaction to increases in D2 stimulation, suggesting abnormal postsynaptic D2 function.


Subject(s)
Corpus Striatum/metabolism , Dopamine/metabolism , Schizophrenia/metabolism , Substance-Related Disorders/metabolism , Adult , Amphetamine/pharmacology , Case-Control Studies , Corpus Striatum/diagnostic imaging , Corpus Striatum/drug effects , Diagnosis, Dual (Psychiatry) , Female , Functional Neuroimaging , Humans , Male , Radionuclide Imaging , Schizophrenia/complications , Schizophrenia/diagnostic imaging , Substance-Related Disorders/complications , Substance-Related Disorders/diagnostic imaging
13.
Eur Respir J ; 38(2): 359-67, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21310884

ABSTRACT

The aim of this study was to examine the causes and outcomes of hospitalisation in patients with pulmonary arterial hypertension (PAH). 205 consecutive hospitalisations occurring between 2000 and 2009 in 90 PAH patients were studied. The leading causes for hospitalisation were right heart failure (RHF; 56%), infection (16%) and bleeding disorders (8%). For patients with RHF, in-hospital mortality was 14% overall, 46% for patients receiving inotropes and 48% for those admitted to the intensive care unit. The predictors for in-hospital mortality were the presence of connective tissue disease (CTD) (OR 4.92), systolic blood pressure <100 mmHg (OR 4.32) and Na ≤ 136 mEq · L(-1) (OR 4.29). Mortality after discharge was 13, 26 and 35% at 3, 6 and 12 months, respectively. World Health Organization functional class prior to admission, renal dysfunction, Charlson comorbidity index, and the presence of CTD were all predictors of mortality after discharge. Hyponatraemia and low systolic blood pressure upon admission and underlying CTD are the main prognostic factors for in-hospital mortality in patients with PAH admitted for RHF. The short-term outcomes after discharge are poor and remarkably worse in patients with underlying CTD or renal impairment. Early recognition of these factors may guide decisions regarding more aggressive therapy, including consideration for lung transplantation.


Subject(s)
Heart Failure/mortality , Hospitalization/statistics & numerical data , Hypertension, Pulmonary/mortality , Adult , Aged , Blood Coagulation Disorders/epidemiology , Cardiotonic Agents/therapeutic use , Connective Tissue Diseases/epidemiology , Familial Primary Pulmonary Hypertension , Female , Heart Failure/drug therapy , Hospital Mortality , Humans , Hyponatremia/epidemiology , Hypotension/epidemiology , Infections/epidemiology , Intensive Care Units/statistics & numerical data , Male , Middle Aged , Prognosis , Prospective Studies , Renal Insufficiency/epidemiology , Treatment Outcome
14.
Int J Clin Pract Suppl ; (165): 4-6, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19958394

ABSTRACT

With recent advances in our understanding of pulmonary hypertension and with ever increasing therapeutic options at our disposal, it remains disappointing that clinical markers of disease progression remain dated. There has long been a search for a more robust clinical correlate than the 6 minute walk test. Resting right heart pressures do not increase linearly with worsening disease, limiting their use as primary endpoints. Some progress has been made however, with 'time to clinical worsening' a composite endpoint of several markers of disease severity. Trials have also been undertaken to evaluate the merits of echocardiographic indices, cardio pulmonary exercise testing and cardiac MRI, with mixed results. With the lack of a sensitive and specific biomarker for pulmonary hypertension, the goal of finding a reproducible endpoint that accurately reflects disease severity and prognosis remains elusive. In this article we discuss relevant endpoints and focus on exercise haemodynamics as a primary endpoint for clinical trials.


Subject(s)
Disease Progression , Endpoint Determination/methods , Exercise Test/methods , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/physiopathology , Clinical Trials as Topic , Endpoint Determination/instrumentation , Hemodynamics , Humans , Physical Endurance , Predictive Value of Tests , Prognosis , Reference Values , Research Design , Walking
15.
Eur Respir J ; 35(1): 95-104, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19643943

ABSTRACT

N-terminal pro-brain natriuretic peptide (NT-proBNP) is a marker of neurohormonal activation that is useful in the diagnosis and prognosis of various forms of pulmonary arterial hypertension (PAH). We sought to characterise and compare NT-proBNP in a cohort of PAH related to systemic sclerosis (PAH-SSc) and idiopathic PAH (IPAH) patients. NT-proBNP levels, collected from PAH-SSc and IPAH patients followed prospectively, were compared and correlated with haemodynamic variables. Cox proportional hazard models were created to assess the predictive value of NT-proBNP. 98 patients (55 PAH-SSc, 43 IPAH) were included. Haemodynamics were similar, except for lower mean pulmonary arterial pressure in PAH-SSc. NT-proBNP levels were significantly higher in PAH-SSc (3,419+/-3,784 versus 1,393+/-1,633 pg x mL(-1); p<0.01) and were more closely related to haemodynamics in PAH-SSc than IPAH. 28 patients died. NT-proBNP predicted survival (hazard ratio (HR) 3.18; p<0.01) in the overall cohort; however, when stratified by group, predicted survival only in PAH-SSc (HR 3.07, p<0.01 versus 2.02, p = 0.29 in IPAH). This is the first description showing NT-proBNP levels are 1) significantly higher in PAH-SSc than IPAH despite less severe haemodynamic perturbations, and 2) stronger predictors of survival in PAH-SSc, suggesting that neurohormonal regulation may differ between PAH-SSc and IPAH. Future studies to define pertinent mechanisms are warranted.


Subject(s)
Hypertension, Pulmonary/blood , Hypertension, Pulmonary/etiology , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Scleroderma, Systemic/complications , Female , Humans , Male , Middle Aged , Prospective Studies
16.
Int J Clin Pract Suppl ; (161): 19-21, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19178602

ABSTRACT

HIV-associated pulmonary arterial hypertension (PAH) is a serious complication of HIV infection and associated with high patient mortality. There are multiple similarities between HIV-associated PAH and idiopathic PAH and standard PAH medications have been used to treat the condition with reported success. Prior to the advent of highly active antiretroviral treatments (HAART), the prevalence of the condition in the HIV-infected population was estimated at 0.5%. In a recently published, large, prospective, multi-centre study performed in the HIV-population across France, the prevalence of HIV-associated PAH was estimated at 0.46%. In this article, we provide an overview of HIV-associated PAH and summarise the methodology, pertinent findings and implications of this important paper.


Subject(s)
HIV Infections/complications , Hypertension, Pulmonary/virology , Female , Genetic Predisposition to Disease , HIV Infections/epidemiology , Humans , Hypertension, Pulmonary/epidemiology , Hypertension, Pulmonary/genetics , Hypertension, Pulmonary/physiopathology , Male , Prevalence
17.
Eye (Lond) ; 23(7): 1609, 2009 Jul.
Article in English | MEDLINE | ID: mdl-18704127
18.
Mol Psychiatry ; 13(10): 918-29, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18414407

ABSTRACT

The exact therapeutic mechanism of action of antipsychotic drugs remains unclear. Recent evidence has shown that second-generation antipsychotic drugs (SGAs) are differentially associated with metabolic side effects compared to first-generation antipsychotic drugs (FGAs). Their proclivity to cause metabolic disturbances correlates, to some degree, with their comparative efficacy. This is particularly the case for clozapine and olanzapine. In addition, the insulin signaling pathway is vital for normal brain development and function. Abnormalities of this pathway have been found in persons with schizophrenia and antipsychotic drugs may ameliorate some of these alterations. This prompted us to hypothesize that the therapeutic antipsychotic and adverse metabolic effects of antipsychotic drugs might be related to a common pharmacologic mechanism. This article reviews insulin metabolism in the brain and related abnormalities associated with schizophrenia with the goals of gaining insight into antipsychotic drug effects and possibly also into the pathophysiology of schizophrenia. Finally, we speculate about one potential mechanism of action (that is, functional selectivity) that would be consistent with the data reviewed herein and make suggestions for the future investigation that is required before a therapeutic agent based on these data can be realized.


Subject(s)
Insulin/metabolism , Schizophrenia/drug therapy , Signal Transduction/drug effects , Animals , Antipsychotic Agents/pharmacology , Antipsychotic Agents/therapeutic use , Humans , Schizophrenia/metabolism , Schizophrenia/physiopathology
20.
Eur Respir J ; 29(3): 469-75, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17079256

ABSTRACT

Combination therapy has been recommended for the treatment of pulmonary arterial hypertension (PAH). However, there is scant information on combination therapy after failure of monotherapy, particularly in patients with scleroderma-associated PAH (PAH-SSD). From a group of 82 consecutive patients with PAH who received initial bosentan monotherapy, a total of 13 idiopathic PAH (IPAH) and 12 PAH-SSD patients requiring additional therapy with sildenafil were studied. Sildenafil was added for clinical deterioration based upon symptoms, New York Heart Association (NYHA) classification or 6-min walk distance (6MWD). Clinical data and haemodynamics were collected at baseline. Assessments were made at 1-3-month intervals. At baseline, there were no differences in demographics, NYHA classification, haemodynamics or 6MWD between the two groups. After initiation of bosentan, both groups experienced clinical improvement but ultimately deteriorated (median time to monotherapy failure 792 versus 458 days for IPAH and PAH-SSD patients, respectively). After addition of sildenafil, more IPAH patients tended to improve in NYHA class (five out of 13 versus two out of 12) and walked further (mean difference in 6MWD 47+/-77 m versus -7+/-40 m) compared with PAH-SSD patients. In conclusion, addition of sildenafil after bosentan monotherapy failure improved New York Heart Association class and 6-min walk distance in idiopathic pulmonary arterial hypertension patients but failed to improve either parameter in scleroderma-associated pulmonary arterial hypertension patients. Additional studies are needed to assess the tolerability and efficacy of this combination in patients with scleroderma-associated pulmonary arterial hypertension.


Subject(s)
Antihypertensive Agents/therapeutic use , Hypertension, Pulmonary/drug therapy , Piperazines/therapeutic use , Sulfonamides/therapeutic use , Sulfones/therapeutic use , Vasodilator Agents/therapeutic use , Adult , Aged , Antihypertensive Agents/adverse effects , Bosentan , Dose-Response Relationship, Drug , Drug Therapy, Combination , Exercise Test/drug effects , Female , Humans , Lung Volume Measurements , Male , Middle Aged , Piperazines/adverse effects , Pulmonary Wedge Pressure/drug effects , Purines/adverse effects , Purines/therapeutic use , Scleroderma, Systemic/complications , Scleroderma, Systemic/drug therapy , Sildenafil Citrate , Sulfonamides/adverse effects , Sulfones/adverse effects , Treatment Outcome , Vasodilator Agents/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...